Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC)

Yasir Y. Elamin, Daniel R. Gomez, Mara B. Antonoff, Jacqulyne P. Robichaux, Hai Tran, Melissa K. Shorter, Jadi M. Bohac, Marcelo Vailati Negrao, Xiuning Le, Waree Rinsurogkawong, Jeff Lewis, Lara Lacerda, Emily B. Roarty, Stephen G. Swisher, Jack A. Roth, Jianjun Zhang, Vassiliki Papadimitrakopoulou, John V. Heymach

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC)'. Together they form a unique fingerprint.

Medicine & Life Sciences